Analyst Research

Report Title Price
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cancer Genetics Inc Announces Exercise of Underwriters' Over-Allotment Option

Thursday, 24 Oct 2013 06:20pm EDT 

Cancer Genetics Inc announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 428,700 shares of common stock at a price of $14.00 per share, bringing the total gross proceeds from the offering to $46 million, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics. Aegis Capital Corp. acted as sole book-running manager for the offering. Feltl and Company, Inc., Cantor Fitzgerald & Co. and Dougherty & Company acted as co-managers for the offering. 

Company Quote

-0.09 -0.78%
2 Jul 2015